Cargando…

What are the hurdles in the pathway of COVID-19 convalescent plasma collection in low-income nations?

Detalles Bibliográficos
Autores principales:	Mukhida, Sahjid, Subhash, Johnson, Vyawahare, Chanda, Das, Nikunja Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240502/ https://www.ncbi.nlm.nih.gov/pubmed/37316386 http://dx.doi.org/10.1016/j.htct.2023.05.003

Ejemplares similares

What is actual condition of working parents about child nurturing and what they have to do?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

When should we be able to divert the cost of tuberculosis to other diseases?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

Should we have to submit a letter to editor only in those journals which previously published our letter?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

Who required the counselling to stop intimate partner violence, victim or perpetrators?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

In need of new drugs: Forgetting current use of the available drugs for tuberculosis
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

Does India’s Zero by 30 Strategic Plan Need the Addition of the Rabies Vaccine to the Universal Immunisation Programme?
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Drones for Medical Supply During Disaster: A Game Changer in “Health for All” Policy
por: Das, Nikunja Kumar, et al.
Publicado: (2023)

Diagnosis and treatment of latent tuberculosis infections in high burden settings: A Herculean task
por: Vyawahare, Chanda, et al.
Publicado: (2023)

Introduction of Diphtheria Component Addition in Immunization During Pregnancy
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Role of GeneXpert MTB/RIF assay for the diagnosis of cervical lymph node tuberculosis and rifampicin resistance
por: Mukhida, Sahjid, et al.
Publicado: (2022)

Can health insurance help to improve the personal and economical health of India?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

How precautionary medicine and public health are attached?
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Reply to the syndemic of “COVID-19 and tuberculosis”
por: Patil, Rajashri A., et al.
Publicado: (2023)

A case series and literature review of infections due to Myroides spp.: identification of contributing factors and emerging antibiotic susceptibility trends
por: Khan, Uzair, et al.
Publicado: (2023)

Pakistan floods: Many lesson for all nations
por: Das, Nikunja K., et al.
Publicado: (2023)

Promoting access to COVID-19 convalescent plasma in low- and middle-income countries
por: Bloch, Evan M., et al.
Publicado: (2021)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

The Aarogya Setu mobile application as a bodyguard against COVID-19
por: Khan, Sameena, et al.
Publicado: (2022)

The true historical origin of convalescent plasma therapy
por: Marson, Piero, et al.
Publicado: (2020)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Translational Phytomedicines against Cancer: Promise and Hurdles
por: Devan, Aswathy R, et al.
Publicado: (2023)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Reply to Role and importance of journal reader: Scientific contribution of letter to editor
por: Das, Nikunja K., et al.
Publicado: (2023)

Convalescent plasma therapy for persistent hepatitis E virus infection
por: Ankcorn, Michael, et al.
Publicado: (2019)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Rhino-orbital cerebral mycosis: a case series of non-mucorales in COVID patients
por: Patil, Rajashri, et al.
Publicado: (2023)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Bridging the epilepsy treatment gap in low- and middle-income nations
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2016)

HLA Antibody Rates Are Not Increased in a Regional Group of Male COVID-19 Convalescent Plasma Donors
por: Juskewitch, Justin E., et al.
Publicado: (2021)

Convalescent plasma: A possible treatment of COVID-19 in India
por: Teixeira da Silva, Jaime A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dglpbaath5q5jl8annrkjpou4k